Skip to main content

The recent post hoc analysis of the EXXELERATE study has also demonstrated that certolizumab-treated patients showed consistent efficacy across baseline RF quartiles in patients with RA.13

EXXELERATE trial
EXXELERATE trial

*Number at Week 2.

Certolizumab=certolizumab pegol; DAS28-CRP=Disease Activity Score 28 with C-reactive protein; IU=international units; LDA=low disease activity; N=number; Q=quartile; RA=rheumatoid arthritis; RF=rheumatoid factor.

Figures adapted from Smolen J, et al. Do high RF titers impact response to TNF inhibitors? Comparison of certolizumab pegol and adalimumab in patients with RA and high titers of RF: A post hoc analysis of a phase 4 trial. ACR Convergence 2023, poster 2148. Used with permission from American College of Rheumatology

 

The post hoc analysis of the EXXELERATE trial showed that certolizumab-treated patients with RA had similar drug concentrations across baseline RF quartiles.13

The post hoc analysis of the EXXELERATE trial showed
The post hoc analysis of the EXXELERATE trial showed

Certolizumab=certolizumab pegol; IU=international units; N=number; Q=quartile; RF=rheumatoid factor; SD=standard deviation.

Figures adapted from Smolen J, et al. Do high RF titers impact response to TNF inhibitors? Comparison of certolizumab pegol and adalimumab in patients with RA and high titers of RF: A post hoc analysis of a phase 4 trial. ACR Convergence 2023, poster 2148. Used with permission from American College of Rheumatology